Seattle Children's Hospital Research Institute - Center for Global Infectious Disease Research

Abraham Bednar

🇨🇳 China

9

Reviewed: June 18, 2023

• - Clinical Protocol Design
• - 6 weeks April - May 2023
• - Pharmaceutical Company

The protocol design provided was comprehensive and very detailed. It laid a strong foundation for our clinical trial, ensuring that all regulatory and ethical considerations were addressed. The attention to detail was impressive.

Beth Mueller

🇩🇪 Germany

9.4

Reviewed: November 8, 2023

• - Health Technology Assessment
• - 10 weeks September - November 2023
• - Pharmaceutical Company

The health technology assessment was thorough and provided valuable insights that were critical to our decision-making process. The team demonstrated a deep understanding of the health economics involved and delivered a well-rounded analysis.

Jessie Sauer

🇹🇷 Turkey

6.5

Reviewed: July 18, 2024

• - Regulatory Submission
• - 8 weeks May - July 2024
• - Pharmaceutical Company

The initial regulatory submission provided was incomplete, requiring additional work to meet the necessary standards. This resulted in unexpected costs and delays. The team corrected the issues, but it should have been right the first time.

Nelson Lemke

🇮🇳 India

5.7

Reviewed: June 10, 2024

• - Project Management
• - 12 weeks March - May 2024
• - Biotech Company

Communication from the project management team was poor, with frequent missed deadlines. This caused significant frustration on our end, as we had to repeatedly chase them for updates. The project eventually got back on track, but the delays were problematic.

Jody Jones

🇹🇷 Turkey

9.3

Reviewed: September 14, 2023

• - Project Management
• - 10 weeks July - September 2023
• - Biotech Company

Project management was seamless, and the team exceeded our expectations. They handled all aspects of the project with professionalism and efficiency, keeping us informed every step of the way.

Raymond Casper DVM

🇸🇦 Saudi Arabia

6

Reviewed: September 12, 2024

• - Health Technology Assessment
• - 8 weeks July - September 2024
• - Pharmaceutical Company

The health technology assessment (HTA) was superficial and did not provide the level of thorough analysis we needed. Some important factors were overlooked, and we had to request additional work to cover these gaps. The overall experience was disappointing.

Florence Zulauf PhD

🇨🇭 Switzerland

8.9

Reviewed: December 1, 2023

• - Medical Writing
• - 5 weeks October - November 2023
• - Biotech Company

The medical writing services provided were of top quality. The documents were clear, precise, and tailored to meet the specific requirements of our regulatory submissions. The team's expertise was evident throughout the process.

Mrs. Bethany Towne

🇪🇸 Spain

9.3

Reviewed: March 12, 2024

• - Market Access Strategy
• - 6 weeks January - February 2024
• - Pharmaceutical Company

The market access analysis provided strategic insights that were crucial to our launch strategy. The team's recommendations were data-driven and actionable, helping us to make informed decisions.

Hugh Mueller PhD

🇰🇷 South Korea

9.2

Reviewed: January 10, 2024

• - Data Visualization
• - 3 weeks December 2023
• - Pharmaceutical Company

The data visualization services were highly effective, making complex data easy to interpret and communicate. The visualizations were impactful and played a crucial role in our stakeholder presentations.

Ms. Hope Harris

🇲🇽 Mexico

9.2

Reviewed: August 20, 2024

• - Regulatory Strategy Consulting
• - 4 weeks July - August 2024
• - Biotech Startup

The regulatory strategy consulting services were thorough and provided us with a clear pathway to regulatory approval. The team's deep understanding of the regulatory landscape was invaluable, and their strategic advice was spot on.